https://www.selleckchem.com/pr....oducts/gf109203x.htm
egistration date June 21, 202. Chinese Clinical Trial Registry, ChiCTR2000034028 (registration date June 21, 202.Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have revolutionized the standard treatment for EGFR T790M-positive non-small cell lung cancer (NSCLC). Osimertinib is one of the third-generation EGFR-TKIs and is currently the most advanced in clinical development. Interstitial lung disease (ILD) is a potentially fatal side effect of osimertinib use. Successful rechallenge with t
Like
Comment
Share
